Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
Primary Purpose
Heart Failure
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AUDICOR then LifeVest then AUDICOR
Sponsored by
About this trial
This is an interventional basic science trial for Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).
- Included in this group are at least five healthy subjects with a self-reported history of heart failure.
- The subject must be 18 years of age or older on the day of screening, with at least 7 subjects 40 years of age or older on the day of screening.
Exclusion Criteria:
- Mental, visual, physical, literacy, and auditory limitations that prevent interaction with the WCD equipment.
- Any acute medical conditions that prevent the following maneuvers: lying on back, lying on the right and left side, standing, sitting, and/ or leaning forward when sitting.
- Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs, and/or chest pain
- Employees or family members of the sponsor.
- Unable or unwilling to provide written informed consent.
Sites / Locations
- MedPace Phase 1 Clinic
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
AUDICOR then LifeVest then AUDICOR
Arm Description
First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
Outcomes
Primary Outcome Measures
To Establish Equivalence Between the Heart Sounds Data Recorded by the LifeVest and FDA-cleared AUDICOR AM System.
Equivalence of the LifeVest device to the AUDICOR device was established by comparing the electromechanical activation time (EMAT) data of each device, collected during quiet sitting. The outcome was reported as the difference in EMAT measured by the LifeVest and AUDICOR device.
Secondary Outcome Measures
Full Information
NCT ID
NCT02825966
First Posted
June 28, 2016
Last Updated
November 6, 2020
Sponsor
Zoll Medical Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02825966
Brief Title
Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
Official Title
Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD): Study Protocol
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zoll Medical Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). These data will be compared with the heart sounds data recorded by an FDA-cleared device AUDICOR AM device.
Detailed Description
To conduct a prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). To show equivalence, these data will be compared with the heart sounds data recorded by an FDA-cleared AUDCIOR AM device .
The study will enroll a minimum of 27 and a maximum of 35 subjects.
Participants will be adult patients (age ≥ 18 years) with at least seven patients over the age of 40 years. In addition, at least five patients with a history of heart failure will be included.
First, participants will wear the AUDICOR-AM device for 15 minutes while sitting quietly. Then, the AUDICOR device will be removed and the participants will wear the WCD for 15 minutes while sitting quietly. Next, while wearing the WCD, participants will perform various activities of daily living, including at least 6 hours of overnight wear. Finally, the WCD will be removed and the participants will wear the AUDICOR again for 15 minutes while sitting quietly.
This is a single center, prospective, observational study. This is a non-significant risk device study as all biological study parameters will be measured noninvasively with the WCD defibrillation capability disabled. In addition, the study device will not be used as a replacement for regularly prescribed therapies or diagnostics.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Each subject first wears the AUDICOR-AM device for 15 minutes while sitting. Then the AUDICOR device is removed and the subject wears the WCD for 12-16 hours. After the WCD wear period, the WCD device is removed and the subject wears the AUDICOR device again for 15 minutes.
Masking
None (Open Label)
Allocation
N/A
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AUDICOR then LifeVest then AUDICOR
Arm Type
Other
Arm Description
First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
Intervention Type
Device
Intervention Name(s)
AUDICOR then LifeVest then AUDICOR
Intervention Description
Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
Primary Outcome Measure Information:
Title
To Establish Equivalence Between the Heart Sounds Data Recorded by the LifeVest and FDA-cleared AUDICOR AM System.
Description
Equivalence of the LifeVest device to the AUDICOR device was established by comparing the electromechanical activation time (EMAT) data of each device, collected during quiet sitting. The outcome was reported as the difference in EMAT measured by the LifeVest and AUDICOR device.
Time Frame
15 minutes of sitting for each group of measurements (Audicor device, then LifeVest, then Audicor device again).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).
Included in this group are at least five healthy subjects with a self-reported history of heart failure.
The subject must be 18 years of age or older on the day of screening, with at least 7 subjects 40 years of age or older on the day of screening.
Exclusion Criteria:
Mental, visual, physical, literacy, and auditory limitations that prevent interaction with the WCD equipment.
Any acute medical conditions that prevent the following maneuvers: lying on back, lying on the right and left side, standing, sitting, and/ or leaning forward when sitting.
Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs, and/or chest pain
Employees or family members of the sponsor.
Unable or unwilling to provide written informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steve Szymkiewicz, MD
Organizational Affiliation
VP Medical Affairs
Official's Role
Study Director
Facility Information:
Facility Name
MedPace Phase 1 Clinic
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
We'll reach out to this number within 24 hrs